461 related articles for article (PubMed ID: 11567966)
1. Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.
Pe'er J; Stefani FH; Seregard S; Kivela T; Lommatzsch P; Prause JU; Sobottka B; Damato B; Chowers I
Br J Ophthalmol; 2001 Oct; 85(10):1208-12. PubMed ID: 11567966
[TBL] [Abstract][Full Text] [Related]
2. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma.
Seregard S; Lundell G; Lax I; af Trampe E; Kock E
Acta Ophthalmol Scand; 1997 Apr; 75(2):148-54. PubMed ID: 9197561
[TBL] [Abstract][Full Text] [Related]
3. PC-10 immunostaining of proliferating cell nuclear antigen in posterior uveal melanoma. Enucleation versus enucleation postirradiation groups.
Pe'er J; Gnessin H; Shargal Y; Livni N
Ophthalmology; 1994 Jan; 101(1):56-62. PubMed ID: 7905616
[TBL] [Abstract][Full Text] [Related]
4. A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques.
Schilling H; Sehu KW; Lee WR
Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):2081-92. PubMed ID: 9331272
[TBL] [Abstract][Full Text] [Related]
5. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
6. Predicting local control of choroidal melanomas following ¹⁰⁶Ru plaque brachytherapy.
Papageorgiou KI; Cohen VM; Bunce C; Kinsella M; Hungerford JL
Br J Ophthalmol; 2011 Feb; 95(2):166-70. PubMed ID: 20889528
[TBL] [Abstract][Full Text] [Related]
7. Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas.
Chiquet C; Grange JD; Ayzac L; Chauvel P; Patricot LM; Devouassoux-Shisheboran M
Br J Ophthalmol; 2000 Jan; 84(1):98-102. PubMed ID: 10611107
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
9. Comparison of microcirculation patterns and MIB-1 immunoreactivity in iris and posterior uveal melanoma.
Chowers I; Folberg R; Livni N; Pe'er J
Ophthalmology; 2001 Feb; 108(2):367-71. PubMed ID: 11158814
[TBL] [Abstract][Full Text] [Related]
10. Irido-cilio-choroidal melanoma in a 5-year-old boy treated by Ru-106 brachytherapy.
Pe'er J; Averbukh E; Frenkel S
Clin Exp Ophthalmol; 2009 Sep; 37(7):742-3. PubMed ID: 19788674
[No Abstract] [Full Text] [Related]
11. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
12. Enucleation after plaque radiotherapy for posterior uveal melanoma. Histopathologic findings.
Shields CL; Shields JA; Karlsson U; Menduke H; Brady LW
Ophthalmology; 1990 Dec; 97(12):1665-70. PubMed ID: 2087297
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of 100 melanomas of the choroid and ciliary body treated by application of ruthenium (RU 106 Rh 106)].
Grange JD; Gerard JP; Ragab M; Quintero P; Delaroche G; Jean-Louis B; Sentenac I; Fontaniere B; Bievelez B
Bull Soc Ophtalmol Fr; 1989 May; 89(5):679-82. PubMed ID: 2590984
[TBL] [Abstract][Full Text] [Related]
14. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.
Barker CA; Francis JH; Cohen GN; Marr BP; Wolden SL; McCormick B; Abramson DH
Brachytherapy; 2014; 13(6):584-90. PubMed ID: 24880583
[TBL] [Abstract][Full Text] [Related]
15. Infiltrating macrophages in extratumoural tissues after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Acta Ophthalmol; 2012 Jun; 90(4):341-9. PubMed ID: 20809904
[TBL] [Abstract][Full Text] [Related]
16. Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas.
Espensen CA; Appelt AL; Fog LS; Thariat J; Gothelf AB; Aznar MC; Kiilgaard JF
Acta Oncol; 2020 Aug; 59(8):918-925. PubMed ID: 32412331
[No Abstract] [Full Text] [Related]
17. Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas.
Toivonen P; Mäkitie T; Kujala E; Kivelä T
Curr Eye Res; 2003 Oct; 27(4):237-45. PubMed ID: 14562175
[TBL] [Abstract][Full Text] [Related]
18. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
19. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.
Mooy CM; de Jong PT; Van der Kwast TH; Mulder PG; Jager MJ; Ruiter DJ
Ophthalmology; 1990 Oct; 97(10):1275-80. PubMed ID: 2243677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
